174 (PB054) - A novel BAD phosphorylation inhibitor combined with EGFR tyrosine kinase inhibitors in EGFR-mutant lung adenocarcinoma treatment

Abstract

Background: The approval and use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant NSCLC has been a breakthrough in clinic. The activation of compensatory pathways of PI3 K/ AKT and/or MEK/MAPK modulates cell survival and drug resistance of lung adenocarcinoma (LUAC). As a convergent downstream signaling node and the determinant, BAD is a potential target to inhibit cell survival and to overcome EGFR TKI resistance in LUAC treatment.